Dipyridamole for coronary artery bypass surgery

A randomized trial to compare the effects of oral and intravenous dipyridamole was conducted in 58 patients undergoing coronary artery bypass graft (CABG) surgery. Preoperative oral administration of dipyridamole resulted in lower plasma drug concentrations in the early postoperative period than perioperative intravenous administration. Postoperative platelet counts were highest in the patients receiving intravenous dipyridamole, intermediate in those receiving oral dipyridamole and lowest in the control group. Postoperative blood loss was significantly reduced with both oral and intravenous dipyridamole. A second randomized trial was conducted in an additional 40 patients undergoing CABG surgery to evaluate the effects of dipyridamole on myocardial platelet and leukocyte deposition and the cardiac release of thromboxane. Twenty patients received intravenous dipyridamole perioperatively. Autologous platelets and leukocytes were labeled with 111In and 99mTc respectively and were infused before release of the crossclamp. Myocardial biopsies were obtained after aortic declamping and indicated that platelets and leukocytes were deposited in the myocardium during reperfusion. Dipyridamole reduced both platelet and leukocyte deposition. Cardiac release of thromboxane B2 occurred in the early postoperative period and was reduced by dipyridamole. In conclusion, dipyridamole preserved platelets and reduced postoperative bleeding and blood product transfusions in patients undergoing CABG surgery. Dipyridamole also reduced cardiac platelet deposition and thromboxane release and may reduce perioperative ischemic injury.